

Comparison of Hemodynamics Recovery Profile and Costs of Remifentanyl Versus Fentanyl-Based Sevoflurane Anesthesia

Remifentanyl ve Fentanyl Temelli Sevofluran Anestezisinin Hemodinami Derlenme Profili ve Maliyetlerinin Karşılaştırılması

Mehmet Selçuk ULUER, MD, Msc,^a
Ahmet TOPAL, MD, Assis.Prof.,^a
Aybars TAVLAN, MD, Assoc.Prof.,^a
Atilla EROL, MD, Assoc.Prof.,^a
Alper KILIÇASLAN, MD, Assis.Prof.,^a
Şeref OTELCİOĞLU, MD, Prof.^a

^aDepartment of
Anesthesiology and Reanimation,
Konya University
Meram Faculty of Medicine,
Konya

Geliş Tarihi/Received: 13.06.2011
Kabul Tarihi/Accepted: 06.01.2012

Yazışma Adresi/Correspondence:
Ahmet TOPAL, MD, Assis.Prof.
Konya University
Meram Faculty of Medicine,
Department of Anesthesiology and
Reanimation, Konya,
TÜRKİYE/TURKEY
ahmettopal@selcuk.edu.tr

ABSTRACT Objective: This trial was designed to compare the effects of fentanyl and remifentanyl on hemodynamic parameters, postoperative recovery, sevoflurane consumption and the cost of anesthetics. **Material and Methods:** Cases that were scheduled to undergo elective laparoscopic cholecystectomy surgery were assigned to two groups with simple random sampling method, as Group F (Fentanyl) and Group R (Remifentanyl), each including 30 patients. The anesthetic induction was initiated by administering 1-2 mg/kg propofol bolus based on the bispectral index (BIS) value followed by 2 µg/kg fentanyl in Group F patients and 1 µg/kg remifentanyl in Group R patients administered in 60 seconds as iv bolus; subsequently, 0.5 mg/kg iv atracurium was administered. For maintenance of anesthesia, 50% oxygen in-air was administered at 4 L/min; the end-tidal sevoflurane concentration was adjusted to achieve a BIS value of 45 to 55. In Group R, remifentanyl 0.25 µg/kg/min infusion was continued. The addition of 0.5 µg/kg fentanyl was planned as required in Group F. Sevoflurane end-tidal concentration and the changing times were recorded. For each case, the sevoflurane consumption was calculated using the Dion formula. **Results:** In Group R, the hemodynamic control, particularly the suppression of response to intubation was more successful than in Group F. The eye opening times and Post Anesthesia Care Unit (PACU) transfer times were shorter in Group R relative to Group F (p=0.001 and p=0.001, respectively). Sevoflurane consumption was lower in the Group R (7.18±3.45 mL) compared to Group F (16.45±7.15 mL) (p=0.001). The total anesthetic drug cost was similar between the groups. **Conclusion:** Compared to fentanyl, remifentanyl provided a better intraoperative hemodynamic control, faster postoperative recovery and a favorable effect on anesthetic drug cost by decreasing sevoflurane consumption, eliminating the disadvantages of its price.

Key Words: Cost control; fentanyl; remifentanyl; sevoflurane

ÖZET Amaç: Bu çalışma, fentanyl ve remifentanalın hemodinamik parametreler, postoperatif derlenme, sevofluran tüketimi ve anestetik maliyeti üzerindeki etkilerini karşılaştırmak amacıyla tasarlandı. **Gereç ve Yöntemler:** Elektif laparoskopik kolesistektomi cerrahi yapılması planlanan olgular, basit tesadüfi örnekleme yöntemiyle her birinde 30 hasta bulunan, Grup F (Fentanyl) ve Grup R (Remifentanyl) olmak üzere iki gruba ayrıldı. Anestezi induksiyonuna, BIS değerine göre bolus tarzında uygulanan 1-2 mg/kg propofol ve Grup F'de 2 µg/kg fentanyl, Grup R'de de 1 µg/kg remifentanyl verilerek başlandı; bunun ardından 0.5 mg/kg atraküryum uygulandı. Anestezi idamesi için, hava içinde %50 oksijen, 4 L/dk şekilde uygulandı; "end-tidal" sevofluran konsantrasyonu BIS değeri 45-55 olacak şekilde ayarlandı. Grup R'de, 0,25 µg/kg/dak remifentanyl infüzyonuna devam edildi. Grup F'de gerektiğinde 0,5 µg/kg fentanyl eklenmesi planlandı. Sevofluran "end-tidal" konsantrasyonu ve değişme zamanları kaydedildi. Her olgu için Dion formülü kullanılarak sevofluran tüketimi hesaplandı. **Bulgular:** Grup R'de hemodinamik kontrolün, özellikle de entübasyona yanıtın baskılanmasının, Grup F'ye göre daha başarılı olduğu gözlemlendi. Göz açma zamanları ve Anestezi Sonrası Bakım Ünitesi (ASBÜ) ne transfer zamanları Grup R'de Grup F'ye göre daha kısaydı (sırasıyla p=0,001 ve p=0,001). Sevofluran tüketimi Grup R'de (7,18±3,45 mL) Grup F'ye (16,45±7,15 mL) göre daha azdı (p=0,001). Toplam anestetik ilaç maliyeti gruplar arasında benzerdi. **Sonuç:** Fentanille karşılaştırıldığında remifentanalın, daha iyi intraoperatif hemodinamik kontrol ve daha hızlı postoperatif derlenme sağladığı ve sevofluran tüketimini azaltıp, kendi fiyat dezavantajını ortadan kaldırarak, anestetik ilaç maliyeti üzerinde olumlu etki yaptığı saptanmıştır.

Anahtar Kelimeler: Maliyet kontrolü; fentanyl; remifentanyl; sevofluran

doi: 10.5336/medsci.2011-25271

Copyright © 2012 by Türkiye Klinikleri

Türkiye Klinikleri J Med Sci 2012;32(3):707-14

Cost-effectiveness studies conducted in the field of anesthesia are focused on developing safe, rapid, inexpensive techniques with a lower risk of complications. Inhaled anesthetics account for approximately 20% of the total drug costs of anesthesia departments.¹ The use of low fresh gas flow combined with opioid administration could decrease the consumption of the inhaled anesthetics.² Comparing remifentanyl to other opioids may provide an advantage in achieving hemodynamic stability during the operation owing to its short half-life, organ-independent elimination, and convenient titration of efficacy. While it is advantageous over other opioids, it is more expensive than the other agents.³⁻⁹

This trial was designed to compare the effects of fentanyl and remifentanyl on intraoperative hemodynamic parameters, postoperative recovery, sevoflurane consumption and the cost of anesthetics, and providing adequate anesthetic depth by bispectral index (BIS) control in laparoscopic cholecystectomy operations.

MATERIAL AND METHODS

This prospective trial included 60 American Society for Anesthesiology (ASA) I-II patients between 18 and 65 years of age, who were scheduled to undergo elective laparoscopic cholecystectomy surgery between June 2010 and October 2010. Konya University Meram Medical Faculty Ethical Committee approved the study protocol. Informed consent in accordance with the Helsinki Declaration was obtained from the patients. Patients with cardiac, renal, hepatic failure or respiratory disease, known hypersensitivity to the investigational drugs, alcohol and drug addicts and those who had used opioid analgesics within the previous days were excluded from the trial.

The cases were assigned to two groups with simple random sampling method, Group F (Fentanyl, n=30) and Group R (Remifentanyl, n=30). Throughout the operation, electrocardiography (ECG), noninvasive blood pressure (NIBP), pulse oximeter (SpO₂), BIS, and neuromuscular transport (NMT) monitorization (Drager infinity kappa,

Drager medical systems inc. Denver, USA) was run for each patient. The patients were pre-oxygenated for three minutes using 100% oxygen before induction. The anesthetic induction was initiated by 1-2 mg/kg propofol bolus administration based on the BIS value followed by 2 µg/kg fentanyl in Group F patients and 1 µg/kg remifentanyl in Group R patients administered in 60 seconds as iv bolus; subsequently, 0.5 mg/kg iv atracurium was administered. After intubation, the patients were connected to the mechanical ventilator (Drager medical systems inc. Denver USA) and were ventilated at a flow rate of 4 L/min with 50% oxygen in-air such that the end-tidal CO₂ partial pressure (EtCO₂) was 35±5 mmHg. Sevoflurane was initiated at an end-tidal concentration of 1%. In Group R, 0.25 µg/kg/min remifentanyl infusion was continued. In Group F, an additional 0.5 µg/kg fentanyl was administered at 30 minutes intervals after the induction and throughout the rest of the surgery. Anesthetic depth was assessed by BIS monitoring. The end-tidal sevoflurane concentration was adjusted to achieve a BIS value between 45-55. Sevoflurane concentration and the changing times were recorded.

In both groups, patients were administered IV ondansetron 4 mg and tramadol 1 mg/kg for postoperative analgesia. After the gallbladder was removed, administration of sevoflurane and remifentanyl was terminated and the time of anesthesia termination was recorded. When the BIS value was ≥80 and the train of four (TOF) value was 75%, the patients were extubated and the total amount of remifentanyl and fentanyl were recorded. The time from the termination of anesthesia to spontaneous eye opening was recorded as the time of eye opening. Upon achieving a Modified Aldrete Score ≥8 (Table 1), the patients were transferred to the post anesthesia care unit (PACU) and this period was recorded as the PACU transfer time. In the PACU, when the Modified Aldrete Score was ≥9, the pain score was ≤3 as per the visual analogue scale (VAS) (Figure 1), and the patient was hemodynamically stable and had no vomiting or nausea, he/she was transferred to the ward, recording this period as the time of transfer from

TABLE 1: Modified aldrete score.

		Score
Level of consciousness	Awake and oriented	2
	Arousable with minimal stimulation	1
	Responsive only to tactile stimulation	0
Physical activity	Able to move all extremities on command	2
	Some weakness in movement of extremities	1
	Unable to voluntarily move extremities	0
Hemodynamic stability	Blood pressure, 15% of baseline MAP value	2
	Blood pressure 15%–30% of baseline MAP value	1
	Blood pressure 30% below baseline MAP value	0
Respiratory stability	Able to breathe deeply	2
	Tachypnea with good cough	1
	Dyspneic with weak cough	0
Oxygen saturation status	Maintains value 90% on room air	2
	Requires supplemental oxygen (nasal prongs)	1
	Saturation, 90% with supplemental oxygen	0

MAP: Mean arterial pressure.

PACU to the ward. The amount of Sevoflurane used during the operation was calculated using the formula ($C = P \times F \times T \times M / 2412 \times D$) described by Dion [C =the amount of inhaled anesthetic used (mL), P =Anesthetic Agent Concentration (%), F =Fresh gas flow (L/min), T =Time (min), M =Molecular weight (g) and D =Density (g/mL)].¹⁰ Mean arterial pressure (MAP), heart rate (HR) and BIS values were recorded for baseline and following induction, at 1 and 5 minutes after the intubation and every 10 minutes thereafter. PACU admission and discharge times and the MAP, HR, pain, VAS at the PACU and the Modified Aldrete Scores for recovery were recorded.

An SPSS program was used for statistical analyses. The descriptive results were expressed as mean±standard deviation. Chi-square test was used

for assessment of gender and ASA score. For all data, the analysis of compliance with the normal distribution regarding the groups was done using the One Sample Kolmogorov-Smirnov test. The Student's t Test and Mann Whitney U Test were used respectively for data that were compliant and non-compliant with the normal distribution, respectively. Two-way analysis of variance was used for the intra-group comparisons that repeated measurements. Bonferroni corrected paired Student's t test was used as the *post hoc* test when this test was significant. The level of significance was set at $p < 0.05$. For the intra-group HR and MAP measurements, the level of significance was set at $p < 0.01$ after the Bonferroni Correction.

RESULTS

There was no statistically significant difference between the groups in the demographics and ASA classifications of the patients, the times of surgery or the anesthesia type ($p > 0.05$) (Table 2).

Mean arterial pressure measurements revealed a statistically significant difference between the groups in the measurements of MAP 1 minute after the induction (MAPind) ($p = 0.039$), MAP 1 minute after the intubation (MAPint) ($p < 0.001$), MAP at 5 minutes (MAP5) ($p < 0.001$), MAP at 10 minutes (MAP10) ($p < 0.001$), MAP at 20 minutes (MAP20) ($p < 0.001$), MAP at 30 minutes (MAP30) ($p = 0.006$), and MAP at 40 minutes (MAP40) ($p = 0.028$). The values were higher in Group F than those in Group R.

For Group F, the intra-group comparison of the basal mean arterial pressure (MAPb) values with the MAP measurements performed at other time points revealed significant differences for MAPind ($p < 0.001$), MAPint ($p = 0.002$), MAP5

	0	1	2	3	4	5	6	7	8	9	10								
No pain																			Severe pain

FIGURE 1: VAS Score.
VAS: Visual analogue scale.

	Group F (n=30)	Group R (n=30)	p
Age (years)	47.10±12.94	48.33±14.71	0.732
Weight (kg)	72.13±8.13	70.47±10.31	0.490
Height (cm)	164.40±7.43	163.57±7.93	0.676
BMI (kg/m ²)	26.69±2.41	26.29±3.01	0.574
Anesthesia Time (min)	50.30±12.78	46.67±11.21	0.247
Surgery Time (min)	39.77±12.74	37.10±10.50	0.380
Gender (K/E)	9/21	6/24	0.371
ASA (I/II)	16/14	11/19	0.194

ASA: American Society of Anesthesiologists; BMI: Body mass index; F: Female; M: Male; SD: Standard deviation.

(p=0.002), MAP10 (p<0.001), MAP20 (p<0.001), MAP30 (p=0.001), MAP40 (p=0.004) and PACU admission mean arterial pressure (MAPpa) (p<0.001) times. As for the intra-group comparison for Group R, a significant difference was detected between the MAPb and MAPind (p<0.001), MAPint (p<0.001), MAPpa (p<0.001), and PACU discharge mean arterial pressure (MAPpd) (p=0.001) times (Figure 2).

Heart rate measurements revealed a significantly higher heart rate at 1 minute after the intubation (HRint) (p=0.003) in Group F than in Group R.

The intra-group comparison of the basal HR values (HRb) with the HRs measured at other time points for both groups showed a significant difference between the HRb and HRint (p=0.007); the HRint was higher in Group F than in Group R. As for Group R, there was a significant difference between HRb and PACU admission HR (HRpa) (p<0.001); the HRpa was higher (Figure 3).

The comparison of the BIS values between the groups revealed no significant difference (p>0.05). The eye opening time and PACU transfer time were significantly shorter in Group R than in Group F (Table 3).

The comparison of the Modified Aldrete and VAS scores between the groups revealed no significant difference in the PACU admission, PACU discharge Modified Aldrete Score and VAS values (p>0.05) (Table 4).




FIGURE 2: MAP data.

*p<0.05: compared to Group R

^αp<0.01: relative to intra-Group F MAPb

^βp<0.01: relative to intra-Group R MAPb

MAP: Mean arterial pressure; MAPb: Basal MAP; MAPind: MAP at induction; MAPint: MAP at intubation; MAP5: MAP at 5 minutes after the intubation; MAP10: MAP at 10 minutes after the intubation; MAP20: MAP at 20 minutes after the intubation; MAP30: MAP at 30 minutes after the intubation; MAP40: MAP at 40 minutes after the intubation; MAPpa: MAP at postanesthesia care unit admission; MAPpd: MAP at discharge from postanesthesia care unit.




FIGURE 3: HR data

* $p=0.003$ compared to Group R

^a $P=0.007$ relative to intra-Group F HRb

^b $P<0.001$ relative to intra-Group R HRb

HR: Heart rate; HRb: Basal HR; HRind: HR at induction; HRint: HR at intubation; HR5: HR at 5 minutes after the intubation; HR10: HR at 10 minutes after the intubation; HR20: HR at 20 minutes after the intubation; HR30: HR at 30 minutes after the intubation; HR40: HR at 40 minutes after the intubation; HRpa: HR at postanesthesia care unit admission; HRpd: HR at discharge from postanesthesia care unit.

The amount of sevoflurane consumption (ml) and sevoflurane cost per patient (Turkish Liras, TL) were higher in Group F than in Group R.

The cost of remifentanyl per patient (TL) was significantly higher than the cost of fentanyl. There was no significant difference between the groups in the total anesthetic drug (AD) cost per patient, and AD cost per patient per minute (TL/min) (Table 5).

DISCUSSION

This trial looked at the effects of fentanyl and remifentanyl, agents commonly used in anesthesia practice, on anesthetic drug cost and the intraoperative hemodynamic and the postoperative recovery characteristics of these agents, accompanied by BIS monitorization. Remifentanyl seemed to exhibit a better perioperative hemodynamic control and a faster postoperative recovery with a lower sevoflurane consumption and similar total anesthetic drug cost.

Fentanyl is 75 to 125 times and remifentanyl is 250 times more potent than morphine.¹¹ Thus, the doses of fentanyl and remifentanyl were determined accordingly and while fentanyl was admin-

istered as bolus, infusion was used for remifentanyl.¹²

Twersky et al. investigated the impact of remifentanyl and fentanyl on the hemodynamic responses to surgical stress in a multi-center trial involving 2438 patients.¹³ Following induction and intubation, lower blood pressures and heart rates were achieved with remifentanyl. The ability to achieve an appropriate anesthetic depth by dose titration with the pharmacokinetic and pharmacodynamic characteristics of remifentanyl renders this agent superior over other opioid drugs.

Özcan et al. compared the effects of remifentanyl and fentanyl on the hemodynamic response secondary to tracheal intubation.¹⁴ In the trial, the first group received 1 $\mu\text{g}/\text{kg}$ fentanyl and the second group received 1 $\mu\text{g}/\text{kg}$ remifentanyl. As a result, 1 $\mu\text{g}/\text{kg}$ remifentanyl was more effective hemodynamically in preventing the stress response secondary to intubation.

In this trial, while the hemodynamic values were stable in both groups, the hemodynamic response to orotracheal intubation and surgical stimuli were better suppressed in patients receiving remifentanyl. During the operation, lower blood

TABLE 3: Eye opening time, PACU transfer time, PACU ward transfer times (Mean±SD).

	Group F (n=30)	Group R (n=30)	p
Eye Opening Time (min)	12.77±4.09*	9.03±1.84	0.001
PACU Transfer Time (min)	21.33±4.99*	17.80±4.06	0.004
PACU Ward Transfer Time (min)	49.87±9.56	45.87±9.45	0.109

PACU: Post-anesthesia care unit; SD: Standard deviation.

*p<0.05 Group F compared to Group R.

TABLE 4: Modified aldrete and VAS scores (Mean±SD).

	Group F (n=30)	Group R (n=30)	p
VAS (PACU admission)	4.23±1.16	3.93±1.20	0.276
VAS (PACU discharge)	2.83±0.46	2.97±0.49	0.460
Modified Aldrete Score (PACU admission)	8.97±0.80	9.20±1.37	0.064
Modified Aldrete Score (PACU discharge)	9.93±0.25	9.97±1.83	0.557

PACU: Post-anesthesia care unit; SD: Standard deviation; VAS: Visual analogue scale.

TABLE 5: The mean total anesthetic drug (AD) use and cost (mean±SD).

	Group F (n=30)	Group R (n=30)	p
Sevoflurane (mL)	16.45±7.15*	7.18±3.45	0.001
Sevoflurane cost per patient (TL)	13.01±5.66*	5.68±2.74	0.001
Fentanyl/remifentanyl cost per patient (TL)	0.79±0.11*	5.79±1.75	0.001
Total AD cost per patient (TL)	13.81±5.69	11.48±3.59	0.063
AD cost per patient per minute (TL/min)	0.27±0.07	0.24±0.05	0.128

AD: Anesthetic drug; TL: Turkish lira.

*p<0.05 Group F compared to Group R.

pressure and heart rate values were obtained in the remifentanyl group. In the postoperative group, the hemodynamic values at PACU admission and discharge were increased in both groups compared to the intraoperative and basal measurements; this was more marked in the remifentanyl group. The more marked increase in Group R may be attributed to the pharmacokinetic characteristics of remifentanyl that is rapidly eliminated right after anesthesia termination. Coşkun et al. used remifentanyl and fentanyl as bolus injection for anesthesia

induction in combination with propofol infusion and as infusion for maintenance.¹⁵ In the remifentanyl group, the spontaneous eye opening time, and extubation time was significantly shorter compared to the fentanyl group.

In a trial, Anthony et al. reported that the time of transfer to PACU was shorter in the remifentanyl group relative to the fentanyl group while there was no difference between the groups in the time of transfer from PACU to the ward.¹⁶ Twersky et al. compared the post-anesthesia recovery characteristics of remifentanyl and fentanyl.¹³ They observed an early response to verbal stimuli and a shorter time of transfer to PACU in the remifentanyl group.

In this trial, the eye opening time of patients was shorter in the remifentanyl group relative to the fentanyl group. A faster recovery from anesthesia was observed with remifentanyl. The time of transfer from the operating room to PACU was also shorter in the remifentanyl group. There was no difference in the time of transfer from the PACU to the ward.

Yıldız et al. compared remifentanyl and alfentanil in laparoscopic cholecystectomy operations they performed using total intravenous anesthesia (TIVA) and detected that 20% and 50% of the patients in the alfentanil and remifentanyl groups respectively needed analgesic administration in the PACU and that analgesic requirement occurred earlier in the remifentanyl group.¹⁷

In our trial, intraoperative tramadol 1 mg/kg was administered for postoperative analgesia; this may account for the lack of a difference between the groups in the PACU admission VAS values. The comparison of the VAS scores between the groups revealed no significant difference between the groups in PACU admission and discharge values. In both groups, the mean PACU admission VAS value was below 5 and the mean PACU discharge value was below 3. Postoperative pain treatment should not be considered a disadvantage for remifentanyl, an agent that enables rapid recovery by rapid elimination provided that the necessary measures are taken.

In trials comparing the quality of anesthesia and costs, anesthesia of equal depth is administered, enabling more reliable results to be obtained. BIS enables an objective assessment of the anesthesia depth by quantitatively measuring the effect of the anesthetic agent on the central nervous system.¹⁸ Thus, it avoids excessive or inadequate anesthetic consumption. The opioids used as an adjunct in general anesthesia are reported to have no effect on the BIS. In a trial investigating the effect of different concentrations of remifentanyl on the BIS between the periods with no painful stimulus below the constant level of propofol infusion and the intubation period, remifentanyl did not affect the BIS values, however, it did prevent the BIS increase associated with laryngoscopy and orotracheal intubation in a dose dependent manner.¹⁹

In our trial, the sevoflurane doses were titrated by using BIS monitoring to achieve an equal-depth anesthesia between the groups. Starting from induction, the BIS values were kept at between 45-55 in both groups. Thus, we could compare the effect of fentanyl and remifentanyl on sevoflurane consumption by achieving an adequate anesthesia depth in both groups. In our trial, sevoflurane consumption was significantly decreased in the remifentanyl group compared to the fentanyl group.

In a trial investigating sevoflurane consumption accompanied by BIS monitoring, the consumption was 17.16 mL/hour and 22.08 mL/hour in the remifentanyl group and control group respectively.²⁰ In another trial investigating the effect of remifentanyl on sevoflurane consumption by entropy monitoring, remifentanyl was used at a dose of 1 µg/kg in the study group; for maintenance, one group was administered 0.1 µg/kg/min remifentanyl while the other received 0.002 mL/kg/min saline infusion and the investigators administering saline infusion reported a significantly lower end-tidal sevoflurane value in the remifentanyl group.²¹

Beers et al. compared the cost-effectiveness of remifentanyl and fentanyl and used 3µg/kg fentanyl in one group and 0.5 µg/kg remifentanyl in the other group for induction, and for the maintenance of anesthesia; the second group was administered 0.2 µg/kg/min of remifentanyl as infusion.²² Sevoflurane consumption was 12 mL in the fentanyl group and 6.7 mL in the remifentanyl group.

In our trial, there was a significant difference between the groups in sevoflurane consumption and sevoflurane cost per patient. In our hospital, the cost of 250 mL sevoflurane is 197.97 TL as of October 2010. The comparison of the opioid costs revealed that the cost was lower in Group F than in Group R. This is an expected finding, due to the 30-fold higher cost of remifentanyl compared to fentanyl. In our hospital, 1 ampoule of fentanyl was purchased (100 µg/2 mL) at 0.450 TL and one vial of 2 mg remifentanyl was purchased at 13.71 TL as of October 2010, while the anesthetic agent cost per patient was 13.81±5.69 TL and 11.48±3.59 TL in Group F and Group R respectively with no significant difference detected. Thus, the cost difference resulting from the low sevoflurane consumption in the remifentanyl group was not reflected in the anesthetic drug cost to the same extent.

In our trial comparing the cost-related and anesthetic characteristics of sevoflurane-fentanyl and sevoflurane-remifentanyl anesthesia during laparoscopy operations, remifentanyl was shown to provide better hemodynamic control, a faster postoperative recovery and in particular a favorable effect on cost by reducing the sevoflurane consumption. In conclusion, the addition of remifentanyl to sevoflurane can be safely used in the anesthetic practice for good intraoperative hemodynamic control and early post-operative recovery without resulting in an increase in cost.

Acknowledgements

We thank Dr. Kemal Tahir Şahin for the statistical analyses of the study.

REFERENCES

- Bach A. Costs of sevoflurane in the perioperative setting. *Anaesthesist* 1998;47(Suppl 1):S87-96.
- Kleinschmidt S, Grundmann U, Rauber K, Bauer M. [Anesthesia with remifentanyl combined with desflurane or sevoflurane in lumbar intervertebral disk operations]. *Anaesthesiol Reanim* 2000;25(6):151-7.
- Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. *Anesthesiology* 1992;76(3):334-41.
- Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE. Comparative pharmacokinetics and pharmacodynamics of remifentanyl, its principle metabolite (GR90291) and alfentanil in dogs. *J Pharmacol Exp Ther* 1997;281(1):226-32.
- Kapila A, Glass PS, Jacobs JR, Muir KT, Hermann DJ, Shiraishi M, et al. Measured context-sensitive half-times of remifentanyl and alfentanil. *Anesthesiology* 1995;83(5):968-75.
- Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, et al. Initial clinical experience with remifentanyl, a new opioid metabolized by esterases. *Anesth Analg* 1995;81(3):619-23.
- Akçalı DT, Coşkun D, Çelebi H. [Principles of outpatient anesthesia]. *Journal of Anesthesia* 2009;17(3):117-32.
- Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, et al. Pharmacokinetics and pharmacodynamics of remifentanyl in volunteer subjects with severe liver disease. *Anesthesiology* 1996;84(4):812-20.
- Altun K, Dinçer PÇ, Et EZ, Göğüş FY. [Comparison of the effects of alfentanil and remifentanyl on postoperative cognitive functions]. *Journal of Anesthesia* 2010;18(4):201-6.
- Dion P. The cost of anaesthetic vapours. *Can J Anaesth* 1992;39(6):633.
- Miller RD, Stoelting RK. *Basics of Anesthesia*. 1st ed. New York: Elsevier Health Scie; 2006. p.697.
- Howie MB, Cheng D, Newman MF, Pierce ET, Hogue C, Hillel Z, et al. A randomized double-blinded multicenter comparison of remifentanyl versus fentanyl when combined with isoflurane/propofol for early extubation in coronary artery bypass graft surgery. *Anesth Analg* 2001;92(5):1084-93.
- Twersky RS, Jamerson B, Warner DS, Fleisher LA, Hogue S. Hemodynamics and emergence profile of remifentanyl versus fentanyl prospectively compared in a large population of surgical patients. *J Clin Anesth* 2001;13(6): 407-16.
- Özcan Ş, Başar H, Anbarcı Ö, Apan A, Büyükoçak Ü, Çağlayan O. [Comparison of the effects of remifentanyl and fentanyl on the hemodynamic response to tracheal intubation]. *Türkiye Klinikleri J Med Sci* 2003;23(3): 204-7.
- Coskun D, Celebi H, Karaca G, Karabiyik L. Remifentanyl versus fentanyl compared in a target-controlled infusion of propofol anesthesia: quality of anesthesia and recovery profile. *J Anesth* 2010;24(3):373-9.
- Kovac AL, Summers KL. Comparison of remifentanyl versus fentanyl general anesthesia for short outpatient urologic procedures. *Signa Vitae* 2009;4(2):23-9.
- Yıldız K, Esmaoğlu A, Doğru K, Tercan E, Boyacı A. [A comparison of alfentanil and remifentanyl accompanying with BIS monitorization for total intravenous anaesthesia]. *Türk Anest Rean Cem Mecmuası* 2002;30(7):309-14.
- Sleigh JW, Andrzejowski J. The bispectral index: a measure of depth of sleep? *Anesth Analg* 1999;88(3):659-61.
- Guignard B, Menigaux C, Dupont X, Fletcher D, Chauvin M. The effect of remifentanyl on the bispectral index change and hemodynamic responses after orotracheal intubation. *Anesth Analg* 2000;90(1):161-7.
- Şahin Ş, Apan A, Büyükoçak Ü, Başar H. [The effect of remifentanyl infusion on sevoflurane consumption with Bis monitoring]. *KÜ Tıp Fak Derg* 2007;9(3):30-5.
- Kim HT, Heo HE, Kwon YE, Lee MJ. Effect of remifentanyl on consumption of sevoflurane in entropy monitored general anesthesia. *Korean J Anesthesiol* 2010;59(4):238-43.
- Beers RA, Calımlım JR, Uddoh E, Esposito BF, Camporesi EM. A comparison of the cost-effectiveness of remifentanyl versus fentanyl as an adjuvant to general anesthesia for outpatient gynecologic surgery. *Anesth Analg* 2000;91(6):1420-5.